Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-label, Single-arm, Intra-subject Dose-escalation Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of Ponesimod in Subjects With Symptomatic Moderate or Severe Chronic GVHD Inadequately Responding to First or Second Line Therapy

NCT02461134 is registered in ClinicalTrials.gov with Actelion as lead sponsor.

NCT NCT02461134
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02461134 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-label, Single-arm, Intra-subject Dose-escalation Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of Ponesimod in Subjects With Symptomatic Moderate or Severe Chronic GVHD Inadequately Responding to First or Second Line Therapy
Lead sponsor
Actelion
Phase
Phase 2
Overall status
Terminated
Start date
September 29, 2016
Completion date
March 3, 2017
Enrollment
1 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

chronic graft versus host disease